290 related articles for article (PubMed ID: 15607933)
1. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
2. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
3. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of platinum(II) oxadiazoline complexes and their in vitro antitumor activity in platinum-sensitive and -resistant cancer cell lines.
Coley HM; Sarju J; Wagner G
J Med Chem; 2008 Jan; 51(1):135-41. PubMed ID: 18072719
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
8. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
10. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
11. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
12. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen.
Alvarez M; Paull K; Monks A; Hose C; Lee JS; Weinstein J; Grever M; Bates S; Fojo T
J Clin Invest; 1995 May; 95(5):2205-14. PubMed ID: 7738186
[TBL] [Abstract][Full Text] [Related]
13. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
Brown JM
Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
[TBL] [Abstract][Full Text] [Related]
14. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
16. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of 2,2':6',2' '-terpyridineplatinum(II) complexes against human ovarian carcinoma.
Lowe G; Droz AS; Vilaivan T; Weaver GW; Park JJ; Pratt JM; Tweedale L; Kelland LR
J Med Chem; 1999 Aug; 42(16):3167-74. PubMed ID: 10447962
[TBL] [Abstract][Full Text] [Related]
18. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
Zák F; Turánek J; Kroutil A; Sova P; Mistr A; Poulová A; Mikolin P; Zák Z; Kasná A; Záluská D; Neca J; Sindlerová L; Kozubík A
J Med Chem; 2004 Jan; 47(3):761-3. PubMed ID: 14736257
[TBL] [Abstract][Full Text] [Related]
19. Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane.
Yu CW; Li KK; Pang SK; Au-Yeung SC; Ho YP
Bioorg Med Chem Lett; 2006 Mar; 16(6):1686-91. PubMed ID: 16386904
[TBL] [Abstract][Full Text] [Related]
20. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]